Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Xynomic Pharmaceuticals Holdings, Inc. (XYNO : OTC)
 
 • Company Description   
Xynomic Pharmaceuticals Holdings Inc. is a biopharmaceutical company. It focuses on in-licensing, developing and commercializing oncology drug candidates. Xynomic Pharmaceuticals Holdings Inc., formerly known as Bison Capital Acquisition Corp., is based in Shanghai, China.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $ Daily Weekly Monthly
20 Day Moving Average: shares
Shares Outstanding: 46.27 (millions)
Market Capitalization: $ (millions)
Beta:
52 Week High: $3.84
52 Week Low: $1.70
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week % %
12 Week % %
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
K. WAH CENTRE 1010 MIDDLE SUITE 3306 HUAIHAI ROAD
-
BEIJING,F4 200031
CHN
ph: 86-21-5418-0212
fax: -
ir@xynomicpharma.com None
 
 • General Corporate Information   
Officers
Yinglin Mark Xu - Chairman; Chief Executive Officer; and President
Wentao Jason Wu - Chief Operating Officer
Jinwei Coco Kou - Chief Financial Officer and the Chief Accounting O
Charles Vincent Prizzi - Director
Thomas Folinsbee - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98421X102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 46.27
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: %
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - -
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - -
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©